Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR | Market Cap | 1.01T |
| Revenue (ttm) | 345.83B |
| Net Income (ttm) | 56.59B |
| Shares Out | 832.57M |
| EPS (ttm) | 67.93 |
| PE Ratio | 17.92 |
| Forward PE | 20.19 |
| Dividend | 8.00 (0.66%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 728,932 |
| Average Volume | 134,534 |
| Open | 1,218.15 |
| Previous Close | 1,217.15 |
| Day's Range | 1,218.15 - 1,250.35 |
| 52-Week Range | 1,025.90 - 1,377.95 |
| Beta | 0.32 |
| RSI | 48.36 |
| Earnings Date | Jan 21, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
Stock market today: Top gainers and losers on Nifty50 and Sensex; check list
Indian stock markets opened flat on Friday, with both Nifty50 and Sensex eventually slipping into the red by afternoon trade. Foreign investors continued their selling spree, while domestic institutio...
Top gainers among Nifty 50 stocks in midday trades today, Jan 23: Asian Paints, Dr. Reddy’s Laboratorie, Hindustan Unilever and more
Indian equity benchmarks were trading lower in midday trade on January 23, with selling pressure seen across broader indices. Despite...
Pharma sector stocks today, Jan 23: Dr. Reddy’s Lab jumps 2.14%, Gland Pharma falls 1.71%, Torrent Pharma down 0.80%
The Indian pharma sector stocks showed mixed performance as of 10:20 AM IST on January 23, 2026. The broader market...
Top gainers among Nifty 50 stocks in midday trades today: Dr. Reddy’s Laboratories, Adani Enterprises, Bharat Electronics and more
Indian equity benchmarks were trading modestly higher in midday deals today. As of 12:25 PM, the Nifty 50 was up...
Dr. Reddy's (RDY) Reports Q3 Earnings with Revenue Growth
Dr. Reddy's (RDY) Reports Q3 Earnings with Revenue Growth
Dr. Reddy's GAAP EPS of ₹14.52, revenue of ₹87.27B
Pharma sector stocks rally today: Dr. Reddy’s Laboratories up 5%, Granules India jumps 4.33%, Strides Pharma jumps 4%
Indian pharmaceutical stocks showed gains in morning trade on January 22, 2026, amid a broader market uptrend. The BSE Sensex...
Top stocks for trade today, Jan 22: Eternal, Dr Reddy’s, Shriram Finance, Bank of India, Nestlé India and more
Indian equity markets are expected to witness stock-specific movements on Thursday, January 22, as investors react to a busy mix...
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Dr. Reddy's (RDY) Gains Approval for Generic Ozempic in India
Dr. Reddy's (RDY) Gains Approval for Generic Ozempic in India
Dr. Reddy's wins India nod for generic Ozempic
Novo Nordisk (NVO) stock is in focus as Dr. Reddy’s (RDY) gets India approval for generic Ozempic, ahead of a planned launch in March. Read more here.
Dr Reddy’s to Start Selling Generic Ozempic in India From March
Indian drugmaker Dr Reddy’s Laboratories Ltd. is planning to launch a generic version of Novo Nordisk A/S’s Ozempic in March after the drug’s patent expiry, becoming one of the first firms to capture ...
Dr. Reddy’s Laboratories Q3 Results: Revenue up 4% YoY to Rs 8,726.8 crore, Profit rises to Rs 1,210 crore
Dr. Reddy’s Laboratories reported a steady set of earnings for the third quarter of FY26, with profit after tax attributable...
Top Q3 results today, January 21: Eternal, Dr Reddy’s Laboratories, Bank of India, Waaree Energies, PNB Housing Finance and more to announce earnings
Several listed companies are scheduled to announce their financial results for the quarter ended December 2025 (Q3 FY26) on Wednesday,...
Dr. Reddy's Q3 Earnings Preview
Cyber Fraud Targeting Drugmaker Dr Reddy's Busted, Rs 2.16 Crore Recovered
Group Pharmaceuticals was due to receive a payment of Rs 2.16 crore from Dr. Reddy's Laboratories. However, hackers gained access to their emails and diverted funds.
Top gainers among Nifty 50 stocks in midday trades today: Dr. Reddy’s, Hindustan Unilever, Kotak Mahindra Bank, HDFC Bank and more
Indian equity benchmarks were trading lower in midday deals on Tuesday, even as select heavyweight stocks managed to post modest...
Pharma sector stocks fall today: Glenmark Pharma drops 1.38%, Aurobindo Pharma downm 1.25%, Sun Pharma falls 0.87, Dr. Reddy’s Lab down 0.48%
The pharma sector stocks in India experienced declines as of 10 AM on January 20, 2026, aligning with broader market...
Dr. Reddy's Laboratories Becomes Oversold (RDY)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Antihistamineeyedrop--Dr. Reddy's launched Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), a generic equivalent of Extra-Str...
Pharma sector stocks today: Natco Pharma jumps 1.24%, Dr. Reddy’s Lab gain 0.32%, Divi’s Laboratories up 0.14%
The Indian pharmaceutical sector showed mixed performance on January 9, 2026, amid a slightly declining broader market. As of approximately...
Pharma generics: Semaglutide patent expiry to open Rs 50bn opportunity; Indian players eye FY27 boost
Semaglutide patent expiries in India, Canada, and Brazil are poised to unlock over Rs 50 billion in revenue for generic drugmakers within 12-15 months. Indian companies like Alkem, Dr Reddy's, and Sun...
Dr Reddy’s shares fall nearly 2% today as JPMorgan flags USFDA setback, cuts target to Rs 1,170
Friday, Jan 2: Shares of Dr Reddy’s Laboratories slipped nearly 2% in Friday’s session after JPMorgan reiterated its ‘Underweight’ rating...
Dr. Reddy’s Laboratories in focus today as JPMorgan flags regulatory setback
Shares of Dr. Reddy’s Laboratories are in focus today, Friday, after JPMorgan maintained an ‘Underweight’ rating on the stock with...
Nifty 50 top losers today, January 1: ITC, Dr. Reddy’s, Bajaj Finance, Tata Consumer Products, ONGC, Cipla and more
Indian equity benchmarks ended the first trading session of 2026 on a mixed note as markets witnessed intraday volatility. The...